1. Home
  2. CIX vs SKYE Comparison

CIX vs SKYE Comparison

Compare CIX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CompX International Inc.

CIX

CompX International Inc.

N/A

Current Price

$23.81

Market Cap

296.5M

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.00

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIX
SKYE
Founded
1993
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
296.5M
44.9M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
CIX
SKYE
Price
$23.81
$1.00
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.75
AVG Volume (30 Days)
13.3K
249.9K
Earning Date
11-05-2025
11-10-2025
Dividend Yield
8.96%
N/A
EPS Growth
2.86
N/A
EPS
1.57
N/A
Revenue
$159,004,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.52
N/A
Revenue Growth
5.52
N/A
52 Week Low
$17.89
$1.02
52 Week High
$32.30
$5.75

Technical Indicators

Market Signals
Indicator
CIX
SKYE
Relative Strength Index (RSI) 61.74 34.07
Support Level $20.29 $1.04
Resistance Level $24.62 $1.27
Average True Range (ATR) 0.76 0.10
MACD 0.34 0.01
Stochastic Oscillator 87.41 2.90

Price Performance

Historical Comparison
CIX
SKYE

About CIX CompX International Inc.

Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's operating segment includes Security Products and Marine Components. The company generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Its geographical segments are the United States, Canada, Mexico, and others, of which the United States accounts for the vast majority of revenue.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: